Greenleaf Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.12M Buy
4,753
+11
+0.2% +$5.13K 0.02% 194
2025
Q4
$2.15M Buy
4,742
+39
+0.8% +$16.8K 0.02% 192
2025
Q3
$1.84M Sell
4,703
-334
-7% -$140K 0.02% 217
2025
Q2
$2.24M Sell
5,037
-729
-13% -$336K 0.02% 179
2025
Q1
$2.8M Buy
5,766
+272
+5% +$127K 0.03% 155
2024
Q4
$2.21M Buy
5,494
+79
+1% +$36.6K 0.02% 181
2024
Q3
$2.52M Buy
5,415
+19
+0.4% +$9.13K 0.02% 162
2024
Q2
$2.53M Buy
5,396
+426
+9% +$185K 0.02% 153
2024
Q1
$2.08M Sell
4,970
-7
-0.1% -$2.96K 0.02% 176
2023
Q4
$2.03M Buy
4,977
+67
+1% +$24.8K 0.02% 176
2023
Q3
$1.71M Buy
4,910
+166
+3% +$58.1K 0.02% 178
2023
Q2
$1.67M Sell
4,744
-255
-5% -$85.9K 0.02% 185
2023
Q1
$1.58M Buy
4,999
+7
+0.1% +$2.1K 0.02% 200
2022
Q4
$1.44M Buy
4,992
+362
+8% +$110K 0.02% 202
2022
Q3
$1.34M Sell
4,630
-30
-0.6% -$8.63K 0.02% 196
2022
Q2
$1.31M Buy
4,660
+296
+7% +$79.2K 0.02% 185
2022
Q1
$1.14M Buy
4,364
+667
+18% +$158K 0.01% 226
2021
Q4
$812K Buy
3,697
+1,607
+77% +$312K 0.01% 297
2021
Q3
$379K Sell
2,090
-1,061
-34% -$207K ﹤0.01% 499
2021
Q2
$635K Sell
3,151
-316
-9% -$66.1K 0.01% 335
2021
Q1
$745K Buy
3,467
+355
+11% +$78K 0.01% 271
2020
Q4
$735K Buy
3,112
+214
+7% +$49.1K 0.01% 244
2020
Q3
$789K Sell
2,898
-115
-4% -$31.7K 0.01% 205
2020
Q2
$875K Buy
3,013
+388
+15% +$105K 0.02% 174
2020
Q1
$625K Buy
2,625
+306
+13% +$70.2K 0.01% 189
2019
Q4
$508K Hold
2,319
0.01% 288
2019
Q3
$393K Buy
2,319
+218
+10% +$38.6K 0.01% 337
2019
Q2
$385K Sell
2,101
-42
-2% -$7.34K 0.01% 344
2019
Q1
$394K Buy
2,143
+335
+19% +$61.9K 0.01% 315
2018
Q4
$300K Buy
1,808
+140
+8% +$24.3K 0.01% 367
2018
Q3
$321K Buy
1,668
+216
+15% +$38.5K 0.01% 375
2018
Q2
$247K Buy
+1,452
New +$225K ﹤0.01% 426
2018
Q1
Sell
-152
Closed -$23K 663
2017
Q4
$23K Sell
152
-30
-16% -$4.44K ﹤0.01% 574
2017
Q3
$28K Buy
+182
New +$27.4K ﹤0.01% 515

Other funds holding VRTX

Greenleaf Trust's VRTX Position: Q1 2026 in Review

Greenleaf Trust increased its Vertex Pharmaceuticals (VRTX) stake by 0.23% in Q1 2026, buying an estimated $5.13K and bringing the position to 4,753 shares worth $2.12M. The position accounts for 0.02% of the portfolio, ranked #194.

Greenleaf Trust first reported a position in VRTX in Q3 2017 and has held it in 34 quarters since. The position peaked at $2.8M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Greenleaf Trust held 4,753 shares of Vertex Pharmaceuticals worth $2.12M as of Q1 2026.
  • Greenleaf Trust bought 11 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.13K.
  • Vertex Pharmaceuticals made up 0.02% of Greenleaf Trust's portfolio in Q1 2026, its #194 holding.
  • Greenleaf Trust first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 34 quarters since.
  • Greenleaf Trust's Vertex Pharmaceuticals position peaked at $2.8M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Greenleaf Trust's 13F filing for Q1 2026, filed 27 Apr 2026.